Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma

Histopathology

Volumn 70, Issue 4, 2017, Pages 643-649

  Vasaturo, Angela ^a   Di Blasio, Stefania ^a   Verweij, Dagmar ^a,b   Blokx, Willeke A M ^b   van Krieken, J Han ^b   de Vries, I Jolanda M ^a,b   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

digital pathology; melanin unmixing; melanoma; multispectral imaging; T cell infiltration

Indexed keywords

MELANIN;

ARTICLE; CD3+ T LYMPHOCYTE; CELL DENSITY; CELL INFILTRATION; DIGITAL IMAGING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEARNING ALGORITHM; MELANOMA; MICROSCOPY; MULTISPECTRAL IMAGING TECHNIQUE; PIGMENTATION; PRIMARY TUMOR; PRIORITY JOURNAL; SKIN BIOPSY; TISSUE DISTRIBUTION; TUMOR ASSOCIATED LEUKOCYTE; ALGORITHM; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; IMMUNOLOGY; PATHOLOGY; PROCEDURES; SKIN TUMOR; SPECTROSCOPY;

ALGORITHMS; DIAGNOSTIC IMAGING; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICROSCOPY; SKIN NEOPLASMS; SPECTRUM ANALYSIS;

EID: 85006246985     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.13070     Document Type: Article

References (33)

1. Miller AJ, Mihm MC. Melanoma. N. Engl. J. Med. 2006; 355; 5.
2. Palmieri G, Capone M, Ascierto M et al. Main roads to melanoma. J. Transl. Med. 2009; 7; 86.
3. Ascierto ML, Melero I, Ascierto PA. Melanoma: from incurable beast to a curable bet. The success of immunotherapy. Front. Oncol. 2015; 5; 152.
4. Niezgoda A, Niezgoda P, Czajkowski R. Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy. BioMed Res. Int. 2015; 2015; 851387.
5. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015; 373; 23–34.
6. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 2015; 7; 97–106.
7. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363; 711–723.
8. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015; 372; 2521–2532.
9. Karagiannis P, Fittall M, Karagiannis SN. Evaluating biomarkers in melanoma. Front. Oncol. 2014; 4; 383.
10. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013; 14; 1014–1022.
11. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012; 12; 298–306.
12. Galon J, Fridman W-H, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007; 67; 1883–1886.
13. Ribas A, Comin-Anduix B, Economou JS et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res. 2009; 15; 390–399.
14. Erdag G, Schaefer JT, Smolkin ME et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012; 72; 1070–1080.
15. Ladányi A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res. 2015; 28; 490–500.
16. Mahmoud SMA, Paish EC, Powe DG et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 2011; 29; 1949–1955.
17. Kmiecik J, Poli A, Brons NHC et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J. Neuroimmunol. 2013; 264; 71–83.
18. Berghoff AS, Ricken G, Widhalm G et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 2015; 66; 289–299.
19. Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114; 1537–1544.
20. van der Laak JAWM, Pahlplatz MMM, Hanselaar AGJM, de Wilde PCM. Hue-saturation-density (HSD) model for stain recognition in digital images from transmitted light microscopy. Cytometry 2000; 39; 275–284.
21. Woo J, Liss M, Muldong M et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J. Transl. Med. 2014; 12; 30.
22. Feng Z, Puri S, Moudgil T et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J. Immunother. Cancer 2015; 3; 47.
23. Mansfield JR. Cellular context in epigenetics: quantitative multicolor imaging and automated per-cell analysis of miRNAs and their putative targets. Methods 2010; 52; 271–280.
24. Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 2014; 70; 46–58.
25. Rahbar M, Naraghi ZS, Mardanpour M, Mardanpour N. Tumor-infiltrating CD8+ lymphocytes effect on clinical outcome of muco-cutaneous melanoma. Indian J. Dermatol. 2015; 60; 212.
26. Ito S, Wakamatsu K. Quantitative analysis of eumelanin and pheomelanin in humans, mice, and other animals: a comparative review. Pigment Cell Res. 2003; 16; 523–531.
27. Zhao L, Josiane Z. Skin image illumination modeling and chromophore identification for melanoma diagnosis. Phys. Med. Biol. 2015; 60; 3415.
28. Mäkitie T, Tarkkanen A, Kivelä T. Comparative immunohistochemical oestrogen receptor analysis in primary and metastatic uveal melanoma. Graefes Arch. Clin. Exp. Ophthalmol. 1998; 236; 415–419. doi:10.1007/s004170050099.
29. Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68+ cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2001; 42; 1414–1421.
30. Orchard GE, Calonje E. The effect of melanin bleaching on immunohistochemical staining in heavily pigmented melanocytic neoplasms. Am. J. Dermatopathol. 1998; 20; 357–361.
31. Shen H, Wu W. Study of melanin bleaching after immunohistochemistry of melanin-containing tissues. Appl. Immunohistochem. Mol. Morphol. 2015; 23; 303–307.
32. Jiang K, Brownstein S, Lam K, Burns B, Farmer J. Usefulness of a red chromagen in the diagnosis of melanocytic lesions of the conjunctiva. JAMA Ophthalmol. 2014; 132; 622–629.
33. Vasaturo A, Halilovic A, Bol KF et al. T cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines. Cancer Res. 2016; 76; 3496–3506.